Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO 2019 Congress

Which are the preferred platforms for IO biomarkers discovery?

Liquid biopsies to predict response or resistance in IO

Date

30 Sep 2019

Session

Which are the preferred platforms for IO biomarkers discovery?

Topics

Immunotherapy

Tumour Site

Presenters

Dominic Rothwell

Authors

D.G. Rothwell

Author affiliations

  • Clinical And Experimental Pharmacology, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Conclusions and perspectives

Presenter: John Haanen

Session: Which are the preferred platforms for IO biomarkers discovery?

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.